NCT06101784View on ClinicalTrials.gov

Single and Multiple Ascending Oral Doses of Avenanthramide

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 9, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Inflammation
Interventions
DRUG

Avenanthramide

In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.

DRUG

Placebo

In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.

Trial Locations (1)

H1T 1N6

RECRUITING

Montreal Heart Institute, Montreal

All Listed Sponsors
collaborator

Ceapro Inc.

INDUSTRY

collaborator

The Montreal Health Innovations Coordinating Center (MHICC)

OTHER

lead

Montreal Heart Institute

OTHER